Array BioPharma and Bristol-Myers Squibb announce strategic collaboration
Bristol-Myers Squibb | May 30, 2017
Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.